Detail akcie IDEAYA Bioscienc Rg online

Business Summary: IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Ideaya Biosciences Inc revenues increased from $0K to $207.8M. Net loss decreased 79% to $30.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 3% to $64.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.81 to -$0.35.